219 related articles for article (PubMed ID: 35440099)
21. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
[TBL] [Abstract][Full Text] [Related]
22. [AL amyloidosis presenting with fluminant multiorgan failure accompanied by rapid progression from MGUS to multiple myeloma].
Tazoe K; Takakuwa T; Makuuchi Y; Kuno M; Harada N; Okamura H; Nishimoto M; Koh H; Nakashima Y; Nakamae H; Hino M
Rinsho Ketsueki; 2022; 63(1):31-36. PubMed ID: 35135949
[TBL] [Abstract][Full Text] [Related]
23. Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.
Landgren O; Zeig-Owens R; Giricz O; Goldfarb D; Murata K; Thoren K; Ramanathan L; Hultcrantz M; Dogan A; Nwankwo G; Steidl U; Pradhan K; Hall CB; Cohen HW; Jaber N; Schwartz T; Crowley L; Crane M; Irby S; Webber MP; Verma A; Prezant DJ
JAMA Oncol; 2018 Jun; 4(6):821-827. PubMed ID: 29710195
[TBL] [Abstract][Full Text] [Related]
24. Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.
Steiner N; Göbel G; Michaeler D; Platz AL; Prokop W; Wolf AM; Wolf D; Duftner C; Gunsilius E
Blood Adv; 2021 Mar; 5(6):1746-1754. PubMed ID: 33749761
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
26. [Pitfalls of monoclonal gammopathy].
Meuleman N
Rev Med Brux; 2013 Sep; 34(4):335-8. PubMed ID: 24195249
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
28. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.
Therneau TM; Kyle RA; Melton LJ; Larson DR; Benson JT; Colby CL; Dispenzieri A; Kumar S; Katzmann JA; Cerhan JR; Rajkumar SV
Mayo Clin Proc; 2012 Nov; 87(11):1071-9. PubMed ID: 22883742
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal gammopathy of undetermined significance].
Hermansen NEU; Silkjær T; Hansen CT; Aagaard TG; Gregersen H
Ugeskr Laeger; 2020 Mar; 182(10):. PubMed ID: 32138824
[TBL] [Abstract][Full Text] [Related]
30. Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study.
Rögnvaldsson S; Aspelund T; Thorsteinsdóttir S; Turesson I; Björkholm M; Landgren O; Kristinsson SY
Eur J Haematol; 2021 Jul; 107(1):137-144. PubMed ID: 33840154
[TBL] [Abstract][Full Text] [Related]
31. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.
Turesson I; Kovalchik SA; Pfeiffer RM; Kristinsson SY; Goldin LR; Drayson MT; Landgren O
Blood; 2014 Jan; 123(3):338-45. PubMed ID: 24222331
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.
Kristinsson SY; Tang M; Pfeiffer RM; Björkholm M; Blimark C; Mellqvist UH; Wahlin A; Turesson I; Landgren O
Blood; 2010 Oct; 116(15):2651-5. PubMed ID: 20610813
[TBL] [Abstract][Full Text] [Related]
35. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos L; Tamariz-Amador LE; Puig N; Cedena MT; Guerrero C; Jelínek T; Johnson S; Milani P; Cordon L; Perez JJ; Lasa M; Termini R; Oriol A; Hernandez MT; Palomera L; Martinez-Martinez R; de la Rubia J; de Arriba F; Rios R; Gonzalez ME; Gironella M; Cabañas V; Casanova M; Krsnik I; Perez-Montaña A; González-Calle V; Rodriguez-Otero P; Maisnar V; Hajek R; Van Rhee F; Jimenez-Zepeda V; Palladini G; Merlini G; Orfao A; de la Cruz J; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; Mateos MV; San-Miguel JF; Paiva B;
J Clin Oncol; 2023 Jun; 41(16):3019-3031. PubMed ID: 36930848
[TBL] [Abstract][Full Text] [Related]
36. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
37. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
38. Monoclonal gammopathy of undetermined significance.
Kyle RA; Rajkumar SV
Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
[TBL] [Abstract][Full Text] [Related]
39. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.
Bida JP; Kyle RA; Therneau TM; Melton LJ; Plevak MF; Larson DR; Dispenzieri A; Katzmann JA; Rajkumar SV
Mayo Clin Proc; 2009 Aug; 84(8):685-93. PubMed ID: 19648385
[TBL] [Abstract][Full Text] [Related]
40. Does my patient with a serum monoclonal spike have multiple myeloma?
Bianchi G; Ghobrial IM
Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
